Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | JX5K9 | — |
administered a Tdap vaccine to a patient who is pregnant; the vaccine was out of range; This non-serious prospective pregnancy case was reported by a other health professional via call center representative and described the occurrence of exposure during pregnancy in a female patient who received DTPa (Reduced antigen) (Boostrix) (batch number JX5K9, expiry date 19-JUN-2028) for prophylaxis. On 09-FEB-2026, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced exposure during pregnancy (Verbatim: administered a Tdap vaccine to a patient who is pregnant) and incorrect storage of drug (Verbatim: the vaccine was out of range). The outcome of the exposure during pregnancy and incorrect storage of drug were not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-FEB-2026 Reporter stated that they administered a Tdap vaccine to a patient who was pregnant, and it turned out that the fridge where the vaccine was out of range, patient did get the vaccine already. Reporter mentioned that during the excursion, Boostrix was exposed to a temperature of 29.2 degree C and was out of range for 4 days (96 hours), starting on Thursday 05-FEB-2026. No further details provided.